NRG raises £50m to start trials of Parkinson's, ALS drug NRG Therapeutics' oversubscribed Series B will fund first-in-human trials of a drug targeting mitochondrial dysfunction in neurodegenerative diseases.

#NRGTherapeutics has secured the funding it needs to take a potentially first-in-class therapy for #neurodegenerativediseases from preclinical development into #humantesting.

pharmaphorum.com/news/nrg-rai...